Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06641245

PREconception Folic Acid Clinical Efficacy (PREFACE) Trial

A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

A multisite randomized controlled trial to determine whether supplementation with (6S)-5-methyltetrahydrofolic acid (5-MTHF) is at least as effective as synthetic folic acid in increasing maternal folate status for protection against neural tube defects (NTDs).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-pregnant females who are:
  • Currently trying to become pregnant;
  • Aged 19-42 years;
  • Low risk for an NTD-affected pregnancy

Exclusion criteria

  • Trying to conceive for ≥6 months (as ~90% of pregnancies occur after 6 months of trying);
  • Diagnosed ovulatory disorders (polycystic ovary syndrome, endometriosis, or menstrual irregularity);
  • More than 2 miscarriages in the past year;
  • Undergoing fertility assistance (including current IVF or intrauterine insemination);
  • Pre-existing medical condition known to impact maternal folate status (malabsorptive and inflammatory bowel diseases, active celiac disease, gastric bypass surgery, type 1 or 2 diabetes mellitus);
  • Lifestyle factors known to impact maternal folate status (current smoking, >6 alcoholic drinks per week, recreational drug use);
  • On the female or male side of those trying to conceive: personal NTD history, previous NTD-affected pregnancy, or personal or family history of other folate sensitive congenital anomalies;
  • Use of folate-inhibiting medications (Chloramphenicol, Methotrexate, Metformin, Sulfasalazine, Phenobarbital, Phenytoin, Primidone, Triamterene, Barbiturates).

Treatment and study plan

Folic Acid

Dietary Supplement

folic acid (0.6 mg)

5-MTHF (5-methyltetrahydrofolate)

Dietary Supplement

0.625 mg/d (6S)-5-MTHF

Primary outcomes

  1. RBC folate

    Time frame: At 6 (± 2) wks gestation (approximate time of neural tube closure)

    •Maternal RBC folate concentrations (nmol/L)

Secondary outcomes

  1. Maternal plasma placental growth factor (pg/mL)

    Time frame: At 18 (± 1) and 30 (± 1) wks gestation

    A novel biomarker with increasing use in clinical practice due to a discriminatory capacity for fetal growth restriction vs a small, but healthy fetus

Other outcomes

  1. Human milk total folate concentrations

    Time frame: At 4 weeks postpartum

    Unmetabolized folic acid, reduced folate forms (nmol/L), and folate binding protein

Study contacts

Contact information is provided by the study sponsor or research team.

Crystal D Karakochuk, PhD

CONTACT

[email protected]

604-822-0421

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Collaborators

  • University of Saskatchewan

Registry information

Acronym: PREFACE

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Oct 15, 2024
Registry last updated
Oct 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.